Respuesta :
I would recommend this option.
c. enter into an alliance with a large European pharmaceutical firm. the product would be manufactured in Europe by the 50/50 joint venture and marketed by the European firm
Their market is in European Community. If they partner with a large European pharmaceutical firm, the reputation of the firm will secure their European market. They will be able to minimize their costs because of the joint venture. In the event that the new medical product will be highly in demand not only in Europe but also in other continent, the small Canadian firm will also be able to partner with big Pharmaceutical companies in any continent to manufacture and distribute their products.
c. enter into an alliance with a large European pharmaceutical firm. the product would be manufactured in Europe by the 50/50 joint venture and marketed by the European firm
Their market is in European Community. If they partner with a large European pharmaceutical firm, the reputation of the firm will secure their European market. They will be able to minimize their costs because of the joint venture. In the event that the new medical product will be highly in demand not only in Europe but also in other continent, the small Canadian firm will also be able to partner with big Pharmaceutical companies in any continent to manufacture and distribute their products.